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Introduction {#s01}
============

Glioblastoma multiforme, the most common and aggressive primary malignant brain tumor, carries a dismal prognosis. Patients with glioblastoma multiforme have a survival rate of less than 10% at five years \[[@bib-001]\]. Particular challenges to treating glioblastoma multiforme are the inability of treatments to reach all tumor cells and its distinct cellular heterogeneity that result in rapid and aggressive relapse \[[@bib-002]\]. Surgical resection is usually inadequate for local control, and residual tumors often lead to recurrent disease. Although sensitive to high doses of radiation, glioblastoma multiforme treatment with radiotherapy is limited by normal tissue toxicity. Moreover, chemotherapy has had only modest effects on improving outcomes for glioma patients, mostly due to the protective and selective characteristics of the blood-brain barrier. Therefore, new therapeutic strategies are urgently needed \[[@bib-003],[@bib-004]\].

Recent developments in tumor immunology, genetics, cell-signaling pathways, and cancer stem cells have significantly contributed to our understanding of gliomagenesis. Even though significant advances in basic research rendered promising results in the preclinical setting, many of these treatments have not yet made their way into the clinic. In this review, we will analyze the latest advances for the treatment of glioblastoma, presenting a critical review of their benefits, drawbacks and their potential use in a clinical setting.

Glioma immunotherapies {#s02}
======================

Glioblastoma multiformes secrete various immunosuppressive cytokines, such as prostaglandin-E2, transforming growth factor-β (TGF-β) and interleukin (IL)-10, that dampen the tumor-specific immune response \[[@bib-005]\]. Currently, there is renewed interest in developing therapies that specifically target this problem. An attractive method is to utilize dendritic cells to generate host immune response against the tumor. Dendritic cells can be employed in various manners: 1) priming of dendritic cells with tumor antigens, followed by re-administration of these cells into the patient \[[@bib-006]\]; 2) mobilization of dendritic cells into brain tumors by using an FMS-like tyrosine kinase 3 ligand (Flt3L) \[[@bib-007]\]; 3) *ex-vivo* expansion of tumor-reactive cytotoxic T lymphocytes (CTLs) by peptide-pulsed dendritic cells \[[@bib-008]\]; and 4) targeting of overexpressed epitopes in glioblastoma multiforme, such as epidermal growth factor receptor variant III (EGFR vIII), by dendritic cell-based vaccines \[[@bib-009]\]. These strategies may serve as potential immunotherapies that target glioblastoma multiformes ([Table 1](#tbl-001){ref-type="table"}).

###### Novel glioma immunotherapeutic targeting strategies

![](medrep-04-18-t001)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic approach           Mechanism                             Target                         Preclinical model   Clinical trial   Reference
  ------------------------------ ------------------------------------- ------------------------------ ------------------- ---------------- ---------------------------
  To elicit host\                Immunization with autologous\         MHCII and T cell\              X                                    \[[@bib-006],[@bib-033]\]
  immune response                DCs                                   costimulatory molecules                                             

  To elicit host\                Cotransfection of Poly (I:C) and\     MHCII and Th1 cell\            X                                    \[[@bib-034]\]
  immune response                siRNA into DCs and glioma cells       induction                                                           

  Recruitment of DC\             Differentiation of precursor cells\   Flt3L targets precursor\       X                                    \[[@bib-007]\]
  to elicit immune\              into DC through STAT3-dependent\      cells                                                               
  repsonse                       mechanism                                                                                                 

  *Ex-vivo* generation of\       Peptide-pulsed DCs for ex-vivo\       IL-2, IL-7, IL-15 targeting\   X                                    \[[@bib-008]\]
  tumor-antigen primed T cells   expansion of CTLs                     CD62L and CCR7                                                      

  DC-based vaccine\              Targeting EGFRvIII                    EGFRvIII                       X                   X                \[[@bib-009],[@bib-010]\]
  and peptide vaccine                                                                                                                      

  Radiolabeled\                  Targeting EGFRvIII                    EGFRvIII                                           X                \[[@bib-011]\]
  monoclonal antibodies                                                                                                                    

  Plasmid-based vaccine          Induction of T-cell immunity\         EphA2                          X                                    \[[@bib-035]\]
                                 against glioma cells                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DC, dendritic cells; MHCII, major histocompatibility complex class II; siRNA, small interference RNA; Poly (I:C), polyriboinosinic polyribocytidylic acid; Th1, type 1 helper T cell; Flt3L, adenovirus expressing human FMS-like tyrosine kinase 3 ligand; STAT3, Signal transducer and activator of transcription 3; CTLs, Cytotoxic T Lymphocytes; IL-2, Interleukin-2; IL-7, Interleukin-7; IL-15, Interleukin-15; CD62L, L-selectin; CCR7, C-C chemokine receptor type 7; EGFRvIII, epidermal growth factor receptor variant III; EphA2, ephrin type-A receptor 2.

EGFRvIII is a cell-surface receptor commonly mutated in malignant gliomas, whose overexpression leads to uncontrolled cell division. Rindopepimut, a 14-mer peptide vaccine against EGFRvIII is currently being tested in Phase III Clinical trial \[[@bib-010]\]. Moreover, EGFRvIII can also be targeted by radiolabeled monoclonal antibodies that are being tested in a Phase II clinical trial \[[@bib-011]\]. Due to their high specificity and potential generation of immune response against the tumor, immunotherapies are currently in the spotlight of glioblastoma multiforme therapies.

Novel gene therapeutic approaches in glioblastoma treatment {#s03}
===========================================================

Gene therapy nowadays offers what appear to be infinite possibilities to target different populations of tumor cells ([Table 2](#tbl-002){ref-type="table"}). It works primarily through (1) immune stimulatory approaches and induction of immunologic memory against the tumor; (2) conditional cytotoxic approaches; and (3) RNA interference-based therapies, utilizing transcriptional inhibition as a therapeutic tool.

###### Novel gene therapies

![](medrep-04-18-t002)

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic approach                Mechanism                                 Target          Preclinical model   Clinical trial   Reference
  ----------------------------------- ----------------------------------------- --------------- ------------------- ---------------- ----------------
  Antigen-based therapies             *In situ* production of mutated hIL-13\   IL-13 alfa 2R   X                                    \[[@bib-024]\]
                                      fused to PE via adenovirus vectors                                                             

  Direct cytotoxic effect and\        Dual therapy: HC adenovirus expressing\   Flt3L           X                   X                \[[@bib-012]\]
  induction of anti-glioma immune\    HC-Ad-TK + immunostimulatory\                                                                  
  responses                           HC-Ad-TetON-Flt3L                                                                              

  Decrease tumor invasion             Reduction of MMP-2 via siRNA              MMP-2           X                                    \[[@bib-036]\]

  Reduce tumor cell proliferation,\   Blocking miR-21 function                  miR-21          X                                    \[[@bib-037]\]
  increase apoptosis                                                                                                                 

  Repression of cancer stem cell\     Up-regulation of miR-128                  miR-128         X                                    \[[@bib-038]\]
  population                                                                                                                         

  Increasing anti-glioma immune\      Inhibition of TGFβ2 through antisense\    TGFβ2                               X                \[[@bib-014]\]
  response                            oligonucleotides                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: hIL-13, human interleukin 13; PE, *Pseudomonas* exotoxin; IL-13 alfa 2R, interleukin 13 receptor alfa 2; HC-Ad-TK, high capacity (HC) adenoviruses expressing the herpes simplex tyrosine kinase; HC-Ad-TetON-Flt3L, immunostimulatory cytokine fms-like tyrosine kinase ligand 3; siRNA, small interference RNA; MMP2, matrix metalloproteinase-2; miR-21, micro-RNA 21; miR-128, micro-RNA 128; TGFβ2, transforming growth factor β 2.

Gene therapy allows targeting of pathways that can induce synergy of both conditional cytotoxic and immune stimulatory approaches. A recent study, which is about to be tested in a clinical trial, developed a combination of newly engineered high-capacity adenoviral vectors that encode both HSV1-TK (conditionally cytotoxic herpes simplex virus type 1 thymidine kinase) and Flt3L. Flt3L, whose expression is under Tet-ON system control, recruits bone marrow-derived dendritic cells to the tumor site, triggering an anti-glioblastoma multiforme-specific immune response. HSV1-TK works through a conditional cytotoxic approach in which, upon virus (HSV1) infection, thymidine kinase (TK) is delivered to tumor cells. In the presence of TK and upon administration of a prodrug these tumor cells end up producing cytotoxic metabolites, which culminate in tumor death. The combination of HSV1-TK and Flt3L has been shown to kill proliferating tumor cells in a rat model, leading to an increased animal survival and the development of a long-term anti-glioma immunological memory \[[@bib-012]\].

Another recent successful approach to block important glioma pro-survival pathways has been transcriptional inhibition through RNA interference. One of the most promising RNA interference tools has been the use of antisense oligonucleotides. They inhibit gene expression at the translational level by binding to a specific RNA sequence. A phase III clinical trial to evaluate the efficacy of antisense transforming growth factor β II (TGFβ2) (in patients is also underway. It is believed that, by silencing the TGFβ2 isoform, it will be possible to reduce glioma growth and proliferation by indirectly activating the immune response \[[@bib-013], [@bib-014]\]

Stem cells and stem cell modification {#s04}
=====================================

A number of *in vitro* and *in vivo* studies have demonstrated the unique migratory capacity of neural and mesenchymal stem cells to target glioma. In the setting of glioblastoma multiforme therapy, mesenchymal stem cells are attractive because it is relatively easy to isolate them from patients \[[@bib-015]\], while neural stem cells have shown more specific migratory potential towards glioblastoma multiforme.

###### Stem cell-based carriers' therapies

![](medrep-04-18-t003)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic approach             Mechanism                               Target        Preclinical\   Clinical\   Reference
                                                                                         model          trial       
  -------------------------------- --------------------------------------- ------------- -------------- ----------- ------------------------------------------------------------------
  Induction of apoptosis in\       NSC/MSC engineered to express\          Tumor cells   X                          \[[@bib-016]\]
  glioma cells                     therapeutic genes, such as TRAIL                                                 

  Selective killing glioma cells   Oncolytic virus delivery                Tumor cells   X                          \[[@bib-039]\]

  Selective killing glioma cells   Expression of suicide genes (CD)\       Tumor cells                  X           \[[@bib-017]\]; [ClinicalTrails.gov](http://ClinicalTrails.gov)\
                                   in NSCs -- HB1.F3-CD                                                             Identifier: NCT 01172964

  Selective killing glioma cells   Delivery of therapeutic agents (scFv)   EGFRvIII      X              X           \[[@bib-018]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NSC, neural stem cell; MSC, mesenchymal stem cell; TRAIL, TNF-related apoptosis-inducing ligand; CD, cytosine deaminase; scFv, single-chain variable fragment; EGFRvIII, epidermal growth factor receptor variant III.

Stem cell-based therapies rely mostly on expression of therapeutic genes and delivery of therapeutic agents ([Table 3](#tbl-003){ref-type="table"}), and offer certain advantages over vector-based approaches. Modified stem cells can not only disperse into the tumor and reach more malignant cells but also allow for longer therapeutic gene expression. Such cells can be modified to express either direct cytotoxic molecules (such as tumor necrosis factor-related apoptosis inducing ligand, TRAIL) \[[@bib-016]\] or suicide genes that can convert pro-drugs into their active agents (cytosine deaminase or HSV-thymidine kinase). Following promising pre-clinical data, recently, a clinical trial was launched using human immortalized neural stem cells expressing a suicide CD gene (cytosine deaminase -- HB1.F3.CD), followed by oral 5-fluocytosine. The introduction of the CD gene in a tumor induces the activation of the pro-drug 5-fluocytosine into 5-fluorouracil, resulting in intratumoral chemotherapy and, consequently, tumor shrinkage. ([ClinicalTrails.gov](http://ClinicalTrails.gov) Identifier: NCT 01172964) \[[@bib-017]\].

Alternatively, stem cells can function as *in situ* factories of therapeutic agents: such as immunomodulatory cytokines, antibodies (single-chain scFv--EGFRvIII) \[[@bib-018]\] or even oncolytic viruses \[[@bib-019]\]. Our lab has focused on the inherent tumor-tropic and adenovirus-replicating capabilities of such cells to target glioblastoma multiforme. We have shown that loading stem cells with conditionally replicative adenovirus (CRAds-pk7) does not significantly compromise their homing abilities, protects the payload from host immunosurveillance and, most importantly, prolongs animal survival better than direct adenovirus injection. Lastly, we noticed that neural stem cell-delivery approaches display superior therapeutic efficacy than mesenchymal stem cells in glioblastoma multiforme \[[@bib-020]\].

Overall, regardless of some pitfalls, carrier stem cells have proven to be a promising and an exciting new therapeutic approach for malignant gliomas.

Applications of nanotechnology in brain tumors {#s05}
==============================================

Nanomaterials offer several therapeutic strategies for the treatment of brain tumors \[[@bib-021], [@bib-022]\]. They can either act as drug carrier systems or induce glioma cytotoxicity directly. Drug carriers consist of polymer or lipid-based systems that allow for intratumoral injection of chemotherapeutic drugs or help such agents to cross the blood-brain barrier \[[@bib-023]\]. Recently, biodegradable polymer-based nanoparticles and gold nanoparticles have been explored as vehicles to target brain tumors \[[@bib-024]-[@bib-027]\]. They are mainly delivered by direct intratumoral injection, *in situ* retention through receptor-mediated endocytosis, transcytosis or membrane permeabilization, and blood-brain barrier disruption.

Once in situ, nanoparticles need an external inducer to generate an oscillatory or rotating momentum to induce glioma cell toxicity. The source can be heat, light or even magnetic field. In fact, induction of nanoparticles via local hyperthermia is already under Phase II study for treatment of brain tumors. Our group has been focused on magnetic field induction of oscillatory microdiscs bound to IL-13Rα2 to kill glioma cells \[[@bib-028]\] ([Table 4](#tbl-004){ref-type="table"}). Our *in vitro* results show that even a low-frequency magnetic field can achieve approximately 90% of cancer cell destruction.

###### Nanoparticle-based therapies

![](medrep-04-18-t004)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic approach                             Mechanism                                Target                        Preclinical\   Clinical\   Reference
                                                                                                                          model          trial       
  ------------------------------------------------ ---------------------------------------- ----------------------------- -------------- ----------- ----------------
  Tumor killing through local\                     SPIO generates heat under alternating\   Tumor cells through direct\                  X           \[[@bib-040]\]
  hyperthermia                                     magnetic field                           injection into the tumor                                 

  Tumor killing through\                           Mechanical oscillation of micro discs\   Tumor cells                   X                          \[[@bib-041]\]
  spin-vortex magnetic discs\                      trigger apoptosis                                                                                 
  under low-frequency alternating magnetic field                                                                                                     

  Use of semiconductor\                            Generation of cytotoxic reactive\        Tumor cells                   X                          \[[@bib-028]\]
  nanomaterials (photo catalyst)                   oxygen species under light exposure                                                               

  Deliver therapeutic drugs\                       Intravenous injection of PMLA\           Tumor cells                   X                          \[[@bib-024]\]
  across BBB                                       platform conjugated w/AON\                                                                        
                                                   therapeutic payload                                                                               

  Deliver therapeutic drugs                        Transferrin conjugated polimersome\      Tumor cells                   X                          \[[@bib-026]\]
                                                   loaded w/doxorubicin                                                                              

  Deliver therapeutic drugs                        Gold nanoparticle drug conjugate\        EGFR                          X                          \[[@bib-025]\]
                                                   (5nm core size)                                                                                   

  MRI Contrast reagent and\                        Iron oxide nanoparticle                  Tumor cells                   X                          \[[@bib-042]\]
  drug delivery                                                                                                                                      

  Deliver therapeutic drugs                        MSC loaded with drug-loaded\             Tumor cells                   X                          \[[@bib-032]\]
                                                   nanoparticles                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: SPIO, superparamagnetic iron oxide nanoparticles; PMLA, polymeric nanobioconjugate drug based on the poly (β-L-malic acid); AON, antisense oligonucleotide; BBB, blood brain barrier; EGFR, epidermal growth factor receptor; MRI, magnetic resonance imaging; MSC, mesenchymal stem cells.

In addition, nanotechnology can be combined with other therapies, such as stem cell-based carriers, offering new concepts for treatment of brain tumors \[[@bib-029],[@bib-030]\]. Drug-loaded nanoparticles can be efficiently taken up by mesenchymal stem cells without affecting the cell viability \[[@bib-031],[@bib-032]\]. Since they can be combined with a variety of drugs that are not able to cross the blood-brain barrier, drug-loaded nanoparticles greatly improved drug biodistribution and their therapeutic effect in brain tumor tissues. Today, they represent a new form of targeted tissue-specific delivery.

Conclusion {#s06}
==========

With the recent progresses made in understanding the molecular and genetic composition of malignant gliomas, promising new targets for therapy have emerged.

What does the future hold? {#s06_01}
--------------------------

The integration of novel agents into existing treatment algorithms remains challenging. In recent years, basic and preclinical studies have revealed multiple new mechanisms of gliomagenesis and corresponding targets for treatment. Nevertheless, much from the translational research still needs to be explored to allow a better connection between basic science discoveries and clinical trials.

What questions remain? {#s06_02}
----------------------

Despite recent advances in glioblastoma multiforme treatment, there are still many open questions: (1) Determining the unique molecular and genetic profiles of tumors from individual patients; (2) Understanding the role of glioblastoma multiforme heterogeneity in therapeutic resistance; (3) Targeting glioma stem cells specifically without interfering with normal cell function or biologic stressors; (4) Improving drug delivery methods across the blood-brain barrier and into the tumor.

An effective treatment of brain tumors requires certain obstacles to be overcome. Anti-cancer agents that have been shown to work well against glioma cells *in vitro* are not optimally effective *in vivo* because they do not reach the desired location in sufficient doses. Therefore, modifications need to be implemented to allow better penetrance throughout the CNS and blood-brain barrier. Although a complete oncobiological understanding can enhance the therapeutic efficacy of traditional anti-glioblastoma strategies, the neurobiological complexity of such a diffuse, limited-access and heterogeneous target structure requires profound studies and new drug delivery concepts. Nanoparticle-based drug delivery systems, *in situ* production of immunomodulatory and anti-angiogenic agents through gene therapy vectors, or cell-based delivery vehicles are presented as promising options.

Only a better understanding of glioma neurobiology and heterogeneity will allow the design of more efficient approaches that are capable of selectively targeting glioma tumor cells. This strategy will spare normal brain tissue, extending patient survival and improving quality of life.
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